Develops gene editing technologies and therapies, focusing on advancing genomic medicine and biotechnological innovations.
Metagenomi, Inc. is a genetic medicines company based in Emeryville, California, pioneering therapeutics development through a metagenomics-derived genome editing toolbox in the United States.
At the core of Metagenomi's innovation are advanced genome editing technologies, including programmable nucleases, base editors, and RNA and DNA-mediated integration systems such as prime editing systems and clustered regularly interspaced short palindromic repeat-associated transposases.
The company has strategically positioned itself in the field with key partnerships. This includes a development, option, and license agreement with Affini-T Therapeutics, Inc. to advance gene-edited T-cell receptor-based therapeutic products for the treatment, prevention, or diagnosis of human cancer. Additionally, Metagenomi collaborates with Ionis Pharmaceuticals, Inc. on a research, development, and commercialization agreement focused on leveraging genome editing technologies to create investigational medicines.
Founded in 2016, Metagenomi, Inc. continues to drive forward genetic medicine advancements, leveraging its cutting-edge technologies and strategic collaborations to address critical medical needs.